The Barron's article had some comments on GENZ:
"Genzyme, at 60, doesn't look much better. It trades for about 50 times this year's projected profits, and it's reliant for the bulk of its growth on a single drug, Renagel. The company's biggest-selling product, Cerezyme, a treatment for Gaucher's disease, an inherited disorder, has started to plateau and faces potential competitive threats.
One new Genzyme drug, Fabrazyme, for treatment of Fabry disease, another inherited condition, faces an uphill fight against a rival drug from TranskaryoticTherapies, whose treatment has shown superior clinical-trial results."
ij
PS. Since many of us are overweighted in biotechs, a suitable list of shorts would make for a good hedge expecially when the sector has had a nice run. Thanks - good idea. |
